首页 > 最新文献

Expert Review of Ophthalmology最新文献

英文 中文
Long term outcomes following anti-VEGF therapy for diabetic macular edema 抗vegf治疗糖尿病黄斑水肿的远期疗效
IF 0.7 Q4 OPHTHALMOLOGY Pub Date : 2022-09-03 DOI: 10.1080/17469899.2022.2131539
Christopher M. Maatouk, Resya Sastry, Rishi P. Singh
ABSTRACT Introduction Anti-VEGF agents have been demonstrated to be more effective than sham or laser in treating center-involving diabetic macular edema (DME) in short-term pivotal trials. The literature regarding long-term outcomes (5 years or more) of anti-VEGF treatments in DME is limited. Areas covered A literature search was conducted using the PubMed and Cochrane Library databases. Key words included ‘diabetic macular edema,’ ‘diabetic retinopathy,’ ‘vascular endothelial growth factor,’ ‘anti-VEGF,’ ‘long*,’ and ‘five-year.’ 21 articles were included in the final review that examined the 5-year visual and anatomic outcomes of anti-VEGF treatments in DME. Combined analysis of the mean 5-year change in visual acuity and central retinal thickness was conducted. Expert opinion Anti-VEGF agents provide significant vision and anatomic improvements to patients with DME through at least 5 years of treatment. Given their minimal adverse effect profile, superior impact on visual and anatomic outcomes, and likely cost benefit, anti-VEGF agents should be initiated as early as possible in individuals with clinically significant DME causing vision loss. Further work is required to identify early indicators of poor treatment response and to develop longer-acting anti-VEGF treatments.
在短期关键试验中,抗vegf药物已被证明比假药或激光更有效地治疗中心性糖尿病黄斑水肿(DME)。关于抗vegf治疗DME的长期结果(5年或更长)的文献是有限的。使用PubMed和Cochrane图书馆数据库进行文献检索。关键词包括“糖尿病黄斑水肿”、“糖尿病视网膜病变”、“血管内皮生长因子”、“抗vegf”、“长*”和“5年”。21篇文章被纳入最终综述,这些文章检查了抗vegf治疗DME的5年视觉和解剖结果。结合5年平均视力变化和中央视网膜厚度进行分析。通过至少5年的治疗,抗vegf药物可以显著改善DME患者的视力和解剖结构。鉴于其最小的不良反应,对视觉和解剖结果的卓越影响,以及可能的成本效益,抗vegf药物应尽早开始用于临床显著的二甲醚导致视力丧失的个体。需要进一步的工作来确定不良治疗反应的早期指标,并开发长效抗vegf治疗。
{"title":"Long term outcomes following anti-VEGF therapy for diabetic macular edema","authors":"Christopher M. Maatouk, Resya Sastry, Rishi P. Singh","doi":"10.1080/17469899.2022.2131539","DOIUrl":"https://doi.org/10.1080/17469899.2022.2131539","url":null,"abstract":"ABSTRACT Introduction Anti-VEGF agents have been demonstrated to be more effective than sham or laser in treating center-involving diabetic macular edema (DME) in short-term pivotal trials. The literature regarding long-term outcomes (5 years or more) of anti-VEGF treatments in DME is limited. Areas covered A literature search was conducted using the PubMed and Cochrane Library databases. Key words included ‘diabetic macular edema,’ ‘diabetic retinopathy,’ ‘vascular endothelial growth factor,’ ‘anti-VEGF,’ ‘long*,’ and ‘five-year.’ 21 articles were included in the final review that examined the 5-year visual and anatomic outcomes of anti-VEGF treatments in DME. Combined analysis of the mean 5-year change in visual acuity and central retinal thickness was conducted. Expert opinion Anti-VEGF agents provide significant vision and anatomic improvements to patients with DME through at least 5 years of treatment. Given their minimal adverse effect profile, superior impact on visual and anatomic outcomes, and likely cost benefit, anti-VEGF agents should be initiated as early as possible in individuals with clinically significant DME causing vision loss. Further work is required to identify early indicators of poor treatment response and to develop longer-acting anti-VEGF treatments.","PeriodicalId":39989,"journal":{"name":"Expert Review of Ophthalmology","volume":"17 1","pages":"307 - 319"},"PeriodicalIF":0.7,"publicationDate":"2022-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48561191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prediction of a reliable method for the estimation of central corneal thickness in diabetic patients with and without diabetic retinopathy 预测一种可靠的方法来估计糖尿病视网膜病变和非糖尿病视网膜病变患者的中心角膜厚度
IF 0.7 Q4 OPHTHALMOLOGY Pub Date : 2022-09-03 DOI: 10.1080/17469899.2022.2138346
Anita Syla Lokaj, Gazmend Kaçaniku, K. Spahiu, Faruk Semiz
ABSTRACT Background This study aimed to analyze the central corneal thickness (CCT) in diabetic patients with and without diabetic retinopathy (DR) by investigating the impacts of other CCT factors such as hemoglobin A1c (HbA1c) levels, diabetes mellitus (DM) duration, and the DR stages. The study also compared the results of two measuring devices – anterior segment-optical coherence tomography (AS-OCT) and ultrasound pachymetry (UP). However, the existing research possesses bias in revealing the precise measurement of CCT. Research design and methods The study enrolled 300 participants who were segregated into three equal groups: group A with DR, group B without DR, and the control group. The study tested the following formulated hypothesis, like the correlation between the age, duration, and HbA1c level of diabetic patients with DR and without DR. The effectiveness of the AS-OCT and UP was assessed through statistical analysis. Results The experiment revealed a considerable statistical difference in the formulated hypothesis and observed that AS-OCT had higher efficacy than UP in estimating CCT in all the groups. Conclusions The study recommends the prompt utilization of devices such as AS-OCT to precisely predict CCT. This could greatly benefit DM patients with retinopathy conditions for better decision-making and reliable measures during glaucoma surgery.
本研究旨在通过研究其他CCT因素如血红蛋白A1c (HbA1c)水平、糖尿病(DM)病程和DR分期的影响,分析伴有和不伴有糖尿病视网膜病变(DR)的糖尿病患者角膜中央厚度(CCT)。本研究还比较了两种测量设备-前段光学相干断层扫描(AS-OCT)和超声厚测仪(UP)的结果。然而,现有的研究在揭示CCT的精确测量方面存在偏差。研究设计与方法研究招募了300名参与者,他们被分为三个相等的组:有DR的A组,没有DR的B组和对照组。本研究检验了以下假设,如糖尿病合并DR和不合并DR患者的年龄、病程、HbA1c水平之间的相关性,并通过统计分析评估AS-OCT和UP的有效性。结果实验发现,在所有组中,AS-OCT在估计CCT方面的有效性均高于UP。结论本研究建议及时使用as - oct等仪器来准确预测CCT。这将极大地有利于糖尿病视网膜病变患者在青光眼手术中更好的决策和可靠的措施。
{"title":"Prediction of a reliable method for the estimation of central corneal thickness in diabetic patients with and without diabetic retinopathy","authors":"Anita Syla Lokaj, Gazmend Kaçaniku, K. Spahiu, Faruk Semiz","doi":"10.1080/17469899.2022.2138346","DOIUrl":"https://doi.org/10.1080/17469899.2022.2138346","url":null,"abstract":"ABSTRACT Background This study aimed to analyze the central corneal thickness (CCT) in diabetic patients with and without diabetic retinopathy (DR) by investigating the impacts of other CCT factors such as hemoglobin A1c (HbA1c) levels, diabetes mellitus (DM) duration, and the DR stages. The study also compared the results of two measuring devices – anterior segment-optical coherence tomography (AS-OCT) and ultrasound pachymetry (UP). However, the existing research possesses bias in revealing the precise measurement of CCT. Research design and methods The study enrolled 300 participants who were segregated into three equal groups: group A with DR, group B without DR, and the control group. The study tested the following formulated hypothesis, like the correlation between the age, duration, and HbA1c level of diabetic patients with DR and without DR. The effectiveness of the AS-OCT and UP was assessed through statistical analysis. Results The experiment revealed a considerable statistical difference in the formulated hypothesis and observed that AS-OCT had higher efficacy than UP in estimating CCT in all the groups. Conclusions The study recommends the prompt utilization of devices such as AS-OCT to precisely predict CCT. This could greatly benefit DM patients with retinopathy conditions for better decision-making and reliable measures during glaucoma surgery.","PeriodicalId":39989,"journal":{"name":"Expert Review of Ophthalmology","volume":"17 1","pages":"361 - 369"},"PeriodicalIF":0.7,"publicationDate":"2022-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43286773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ultrasonic ocular dimensions and anthropometry in normal and myopic eyes: a case-control study 正常和近视眼的超声眼尺寸和人体测量:一项病例对照研究
IF 0.7 Q4 OPHTHALMOLOGY Pub Date : 2022-09-03 DOI: 10.1080/17469899.2022.2126832
F. Jinadu, Iskilu Adekunle Jolaoso, Modupe balagun, T. Ottun, Ufuoma Oluwaseyi Olumodeji, A. Olumodeji
ABSTRACT Background We compared ultrasonic ocular axial length and vitreous chamber depth, and physical anthropometry in normal and myopic African adults due to sparse related data in this setting. Research design and methods This was a hospital-based, case-control study in which 175 myopes and 175 emmetropes, recruited by convenience sampling, at General Hospital Epe, Lagos, had their anthropometry and refractive status determined; and ocular axial length and vitreous chamber depth measured with A- and B-mode ocular ultrasonography. Data was analyzed using appropriate inferential statistics and level of significance set at 0.05. Results Mean ocular axial length in normal, mild, moderate and severe myopia was 22.45mm, 23.54mm, 23.79mm, and 25.56mm while mean vitreous chamber depth in normal, mild, moderate, and severe myopia was 15.45mm, 16.63mm, 16.84mm, and 18.68mm, respectively. Males had significantly longer axial length and vitreous chamber depth than females. Correlation between weight, height and BMI and refractive status among myopes was insignificant. There was consistency between A- and B-mode ultrasonography ocular axial length and vitreous chamber measurements with a Cronbach’s Alpha of 0.888 and 0.842, respectively (p<0.001). Conclusion Ocular axial length and vitreous chamber depth increased with the severity of myopia with no correlation of anthropometry with refractive status among African myopes.
背景:由于相关数据较少,我们比较了正常和近视非洲成年人的超声眼轴长度和玻璃体腔深度,以及人体测量。研究设计和方法这是一项基于医院的病例对照研究,通过方便抽样从拉各斯Epe总医院招募175名近视患者和175名近视患者,确定他们的人体测量和屈光状态;A、b超测量眼轴长和玻璃体腔深度。数据分析采用适当的推断统计,显著性水平设为0.05。结果正常、轻度、中度和重度近视的平均眼轴长分别为22.45mm、23.54mm、23.79mm和25.56mm;正常、轻度、中度和重度近视的平均眼轴深分别为15.45mm、16.63mm、16.84mm和18.68mm。雄性的眼轴长度和玻璃体腔深度明显长于雌性。近视患者的体重、身高、BMI与屈光状态的相关性不显著。A、b超眼轴长与玻璃体腔测量值具有一致性,Cronbach’s Alpha值分别为0.888和0.842 (p<0.001)。结论非洲近视患者眼轴长度和玻璃体腔深度随近视严重程度的增加而增加,人体测量与屈光状态无相关性。
{"title":"Ultrasonic ocular dimensions and anthropometry in normal and myopic eyes: a case-control study","authors":"F. Jinadu, Iskilu Adekunle Jolaoso, Modupe balagun, T. Ottun, Ufuoma Oluwaseyi Olumodeji, A. Olumodeji","doi":"10.1080/17469899.2022.2126832","DOIUrl":"https://doi.org/10.1080/17469899.2022.2126832","url":null,"abstract":"ABSTRACT Background We compared ultrasonic ocular axial length and vitreous chamber depth, and physical anthropometry in normal and myopic African adults due to sparse related data in this setting. Research design and methods This was a hospital-based, case-control study in which 175 myopes and 175 emmetropes, recruited by convenience sampling, at General Hospital Epe, Lagos, had their anthropometry and refractive status determined; and ocular axial length and vitreous chamber depth measured with A- and B-mode ocular ultrasonography. Data was analyzed using appropriate inferential statistics and level of significance set at 0.05. Results Mean ocular axial length in normal, mild, moderate and severe myopia was 22.45mm, 23.54mm, 23.79mm, and 25.56mm while mean vitreous chamber depth in normal, mild, moderate, and severe myopia was 15.45mm, 16.63mm, 16.84mm, and 18.68mm, respectively. Males had significantly longer axial length and vitreous chamber depth than females. Correlation between weight, height and BMI and refractive status among myopes was insignificant. There was consistency between A- and B-mode ultrasonography ocular axial length and vitreous chamber measurements with a Cronbach’s Alpha of 0.888 and 0.842, respectively (p<0.001). Conclusion Ocular axial length and vitreous chamber depth increased with the severity of myopia with no correlation of anthropometry with refractive status among African myopes.","PeriodicalId":39989,"journal":{"name":"Expert Review of Ophthalmology","volume":"17 1","pages":"343 - 351"},"PeriodicalIF":0.7,"publicationDate":"2022-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46392369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Refractive surgery current status: expanding options 屈光手术现状:选择范围不断扩大
IF 0.7 Q4 OPHTHALMOLOGY Pub Date : 2022-07-04 DOI: 10.1080/17469899.2022.2108405
M. Packer
Independence from eyeglasses and contact lenses has significant value: ‘The global refractive surgery devices market size was valued at USD 168.2 million in 2020 and is expected to expand at a compound annual growth (CAGR) of 7.7% from 2021 to 2028’ [1]. In addition, ‘Global demand for refractive surgical procedures (laser refractive surgery, presbyopiacorrecting surgery, RLE [Refractive Lens Exchange], and phakic IOL implantation) is expected to grow at a compound annual rate of 9.6% from 2020 to 2025, with annual surgical volume increasing from 3.6 million to 5.8 million procedures’ [2]. Considering the United States alone, it has been reported that ‘The vision correction market generated professional service fees of over $5 billion in 2016 and by 2019 it increased to $6.3 billion mainly provided by independent eye care providers’ [3]. These numbers reflect the high levels of satisfaction achieved with refractive procedures. For example, ‘98.7% of all patients were satisfied or very satisfied after their LASIK surgery’ [4], and ‘99.4% of 1,542 patients surveyed’ stated that they would elect to have the EVO implantable collamer lens (ICL) again [5]. As options for refractive correction have increased, the range of potential surgical candidates has broadened. Today, procedures are available for virtually any type of refractive error, as well as presbyopia. Establishing candidacy for refractive surgery involves assessment of the patient’s motivation and medical condition. The ideal candidate is highly motivated and has a normal visual system apart from refractive error and/or presbyopia. Every incremental decrease in motivation or increase in pertinent findings alters the risk benefit ratio, until the balance swings away from intervention. However, risks related to physical findings may be mitigated by the choice of procedure. Common significant findings that increase surgical risk or impact the choice of procedure include ocular surface disease [6], signs that increase suspicion of corneal ectasia [7], corneal endothelial insufficiency [8], shallow anterior chamber depth or narrow anterior chamber angle [9], incipient or frank cataract [10], signs of ocular inflammation or uveitis [11], glaucoma [12], macular disorders [13], and predisposing lesions that increase the risk of retinal detachment [14]. Age and refractive error primarily determine the choice of procedure, while physical findings play an important secondary role. In addition, patient expectations may influence the decision. For example, knowledge of LASIK is widespread due to its high-profile introduction in the late 1990s [15], extensive marketing by corporate laser vision centers [16] and subsequent controversies regarding untoward outcomes [17]. Because it is commonly equated with refractive surgery, patients may arrive at the doctor’s office expecting to be offered LASIK and unaware that other options exist. All else being equal, it is sometimes easier for a doctor to simply agree
独立于眼镜和隐形眼镜具有重要价值:“全球屈光手术设备市场规模在2020年价值1.682亿美元,预计从2021年到2028年将以7.7%的复合年增长率(CAGR)扩大。”此外,从2020年到2025年,全球对屈光手术(激光屈光手术、老花眼矫正手术、RLE [refractive Lens Exchange]和晶状体人工晶状体植入术)的需求预计将以9.6%的复合年增长率增长,年手术量将从360万例增加到580万例。仅以美国为例,据报道,“视力矫正市场在2016年产生了超过50亿美元的专业服务费,到2019年,这一费用增加到63亿美元,主要由独立眼科保健提供商提供”。这些数字反映了屈光手术的高满意度。例如,“98.7%的患者在LASIK手术后满意或非常满意”,“在1542名接受调查的患者中,99.4%的人表示他们会再次选择EVO植入式晶体(ICL)”。随着屈光矫正的选择增加,潜在的手术选择范围也扩大了。今天,几乎所有类型的屈光不正和老花眼都可以使用手术。建立候选屈光手术包括评估患者的动机和医疗状况。理想的候选人是高度积极的,除了屈光不正和/或老花眼之外,有正常的视觉系统。动机的每一次减少或相关发现的每一次增加都会改变风险收益比,直到平衡偏离干预。然而,与物理检查结果相关的风险可以通过选择手术来减轻。常见的增加手术风险或影响手术选择的重要发现包括眼表疾病[6],增加角膜扩张嫌疑的体征[7],角膜内皮功能不全[8],前房深度浅或前房角度窄[9],早期或明显的白内障[10],眼部炎症或葡萄膜炎的体征[11],青光眼[12],黄斑疾病[13],以及增加视网膜脱离风险的易感病变[14]。年龄和屈光不正是决定手术选择的主要因素,而体格检查则起次要作用。此外,病人的期望可能会影响决定。例如,由于LASIK在20世纪90年代末的高调推出,企业激光视觉中心的广泛营销,以及随后关于不良后果的争议,LASIK的知识被广泛传播。因为它通常等同于屈光手术,患者可能会在到达医生办公室时期望接受LASIK手术,而不知道还有其他选择。在其他条件相同的情况下,医生有时更容易同意病人的意见,而不是就其他可能带来好处的手术方法进行教育。例如,SMILE(小切口晶状体摘除)矫正近视和散光的范围与LASIK相同,但术后干眼症的风险较低。EVO ICL比LASIK或SMILE矫正近视的范围更广,EVO Toric ICL也矫正散光,这些镜片有几个优点,包括保存角膜[19]和晶状体[20],不增加干眼综合征[21],不增加未来与年龄相关的白内障手术的复杂性[23],以及可移除性[23]。这些替代方案应被描述为任何可能被视为候选人的患者知情同意过程的一部分。有晶状体屈光透镜,如EVO ICL,传统上“仅限于不适合激光视力矫正的患者”,现在正成为屈光手术的首选。EVO ICL的全球采用在过去十年中显著增长,最近的FDA批准为更大的扩展奠定了基础。由于中央端口的设计,提高了安全性,有效地解决了大范围的屈光不正和更大的患者便利性,使EVO成为一个有吸引力的选择[5]。我们甚至看到了屈光手术诊所的出现,专门用于EVO植入。正如一位作者所指出的,“我已经成功地为我的病人提供EVO Visian ICL超过4年了,尽管来自提供激光视力矫正手术的同事的激烈竞争,我发现我的手术量在逐年稳步增长。”美国FDA对EVO ICL的临床研究明确证明了EVO/EVO+球形和环形ICL镜片用于矫正近视和近视伴散光的安全性和有效性。在这项临床试验中,327名受试者的629只眼睛,87。 6%的眼术后未矫正视力为20/20或更好。90.5%的眼距目标在0.50 D以内,98.9%的眼距目标在1.00 D以内。98.5%的眼术后矫正视力等于或优于术前矫正视力。
{"title":"Refractive surgery current status: expanding options","authors":"M. Packer","doi":"10.1080/17469899.2022.2108405","DOIUrl":"https://doi.org/10.1080/17469899.2022.2108405","url":null,"abstract":"Independence from eyeglasses and contact lenses has significant value: ‘The global refractive surgery devices market size was valued at USD 168.2 million in 2020 and is expected to expand at a compound annual growth (CAGR) of 7.7% from 2021 to 2028’ [1]. In addition, ‘Global demand for refractive surgical procedures (laser refractive surgery, presbyopiacorrecting surgery, RLE [Refractive Lens Exchange], and phakic IOL implantation) is expected to grow at a compound annual rate of 9.6% from 2020 to 2025, with annual surgical volume increasing from 3.6 million to 5.8 million procedures’ [2]. Considering the United States alone, it has been reported that ‘The vision correction market generated professional service fees of over $5 billion in 2016 and by 2019 it increased to $6.3 billion mainly provided by independent eye care providers’ [3]. These numbers reflect the high levels of satisfaction achieved with refractive procedures. For example, ‘98.7% of all patients were satisfied or very satisfied after their LASIK surgery’ [4], and ‘99.4% of 1,542 patients surveyed’ stated that they would elect to have the EVO implantable collamer lens (ICL) again [5]. As options for refractive correction have increased, the range of potential surgical candidates has broadened. Today, procedures are available for virtually any type of refractive error, as well as presbyopia. Establishing candidacy for refractive surgery involves assessment of the patient’s motivation and medical condition. The ideal candidate is highly motivated and has a normal visual system apart from refractive error and/or presbyopia. Every incremental decrease in motivation or increase in pertinent findings alters the risk benefit ratio, until the balance swings away from intervention. However, risks related to physical findings may be mitigated by the choice of procedure. Common significant findings that increase surgical risk or impact the choice of procedure include ocular surface disease [6], signs that increase suspicion of corneal ectasia [7], corneal endothelial insufficiency [8], shallow anterior chamber depth or narrow anterior chamber angle [9], incipient or frank cataract [10], signs of ocular inflammation or uveitis [11], glaucoma [12], macular disorders [13], and predisposing lesions that increase the risk of retinal detachment [14]. Age and refractive error primarily determine the choice of procedure, while physical findings play an important secondary role. In addition, patient expectations may influence the decision. For example, knowledge of LASIK is widespread due to its high-profile introduction in the late 1990s [15], extensive marketing by corporate laser vision centers [16] and subsequent controversies regarding untoward outcomes [17]. Because it is commonly equated with refractive surgery, patients may arrive at the doctor’s office expecting to be offered LASIK and unaware that other options exist. All else being equal, it is sometimes easier for a doctor to simply agree","PeriodicalId":39989,"journal":{"name":"Expert Review of Ophthalmology","volume":"17 1","pages":"231 - 232"},"PeriodicalIF":0.7,"publicationDate":"2022-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43843366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Hyalocyte functions and immunology 透明细胞功能和免疫学
IF 0.7 Q4 OPHTHALMOLOGY Pub Date : 2022-07-04 DOI: 10.1080/17469899.2022.2100763
S. Boneva, Julian Wolf, Peter Wieghofer, J. Sebag, C. Lange
ABSTRACT Introduction Vitreous hyalocyte functions have only recently been explored in-depth. These macrophage-like cells play critical roles in immunologic surveillance and physiology of the developing and adult eye. Areas covered Hyaloid vasculature involution during embryogenesis, synthesis and degradation of vitreous components during development and aging, and maintenance of vitreous transparency will be discussed. This article also reviews immunologic features during development and in the adult. Expert opinion Recent transcriptional analyses have demonstrated that despite similarity to other myeloid cell populations such as microglia and monocyte-derived macrophages, hyalocytes possess a distinct expression profile and molecular signature. Hyalocytes are important in hyaloid vasculature involution during development, ocular immune privilege and immune surveillance, synthesis and degradation of vitreous components, as well as migration and phagocytic activity during adulthood.
摘要引言玻璃体透明细胞的功能直到最近才得到深入的探索。这些巨噬细胞样细胞在发育中的眼睛和成年眼睛的免疫监测和生理学中起着关键作用。将讨论胚胎发生过程中透明质血管系统退化、发育和衰老过程中玻璃体成分的合成和降解以及玻璃体透明度的维持等方面。本文还综述了发育过程中和成人的免疫学特征。专家意见最近的转录分析表明,尽管与其他骨髓细胞群体(如小胶质细胞和单核细胞衍生的巨噬细胞)相似,但透明细胞具有不同的表达谱和分子特征。透明质细胞在发育过程中的玻璃样脉管系统退化、眼睛免疫特权和免疫监视、玻璃体成分的合成和降解以及成年期的迁移和吞噬活动中起着重要作用。
{"title":"Hyalocyte functions and immunology","authors":"S. Boneva, Julian Wolf, Peter Wieghofer, J. Sebag, C. Lange","doi":"10.1080/17469899.2022.2100763","DOIUrl":"https://doi.org/10.1080/17469899.2022.2100763","url":null,"abstract":"ABSTRACT Introduction Vitreous hyalocyte functions have only recently been explored in-depth. These macrophage-like cells play critical roles in immunologic surveillance and physiology of the developing and adult eye. Areas covered Hyaloid vasculature involution during embryogenesis, synthesis and degradation of vitreous components during development and aging, and maintenance of vitreous transparency will be discussed. This article also reviews immunologic features during development and in the adult. Expert opinion Recent transcriptional analyses have demonstrated that despite similarity to other myeloid cell populations such as microglia and monocyte-derived macrophages, hyalocytes possess a distinct expression profile and molecular signature. Hyalocytes are important in hyaloid vasculature involution during development, ocular immune privilege and immune surveillance, synthesis and degradation of vitreous components, as well as migration and phagocytic activity during adulthood.","PeriodicalId":39989,"journal":{"name":"Expert Review of Ophthalmology","volume":"17 1","pages":"249 - 262"},"PeriodicalIF":0.7,"publicationDate":"2022-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48429843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
The effect of intravitreal dexamethasone implantation on diabetic macular edema refractory to anti-vascular endothelial growth factor treatment 玻璃体内地塞米松植入治疗抗血管内皮生长因子治疗难治性糖尿病黄斑水肿的疗效
IF 0.7 Q4 OPHTHALMOLOGY Pub Date : 2022-07-04 DOI: 10.1080/17469899.2022.2118715
Kiyoung Kim, E. Kim, Do Gyun Kim, Seung-Young Yu
ABSTRACT Purpose To evaluate the efficacy and safety of intravitreal dexamethasone (DEX) implantation for diabetic macular edema (DME) that proved unresponsive to previous anti-vascular endothelial growth factor (VEGF) treatment. Methods This prospective interventional study recruited 91 patients with refractory DME after previous anti-VEGF treatments in one or both eyes. All patients were followed up for at least 12 months. Best-corrected visual acuity (BCVA), central subfield thickness (CST) and macular volume were measured. Results Over the 12 months, a mean of 2.1 ± 0.8 DEX implantations were administered per eye; 26 eyes (28.9%) received 1 implantation, 31 (34.4%) received 2, and 34 (36.7%) received 3. BCVA was significantly improved in the first 6 months, from 54.8 to 59.5 letters. Both CST and macular volume decreased significantly after DEX implantation and maintained these improvements for at least 12 months. Subjects who needed the second DEX implantation had a greater number of prior anti-VEGF injections than did those who needed only one implantation (6.0 vs 3.0). Conclusions Two-thirds of refractory DME required less than two DEX implantations to maintain a dry macula for 12 months. Early switching to intravitreal DEX can be considered as the second-line therapeutic option, especially during the COVID-19 pandemic.
摘要目的评价玻璃体内地塞米松(DEX)植入治疗糖尿病黄斑水肿(DME)的疗效和安全性,该水肿对先前的抗血管内皮生长因子(VEGF)治疗无效。方法本前瞻性介入研究招募了91例单眼或双眼接受过抗VEGF治疗的难治性DME患者。所有患者均接受了至少12个月的随访。测量最佳矫正视力(BCVA)、中心亚视野厚度(CST)和黄斑体积。结果在12个月内,平均每只眼睛植入2.1±0.8个DEX;26眼(28.9%)接受了1次植入,31眼(34.4%)接受了2次植入,34眼(36.7%)接受了3次植入。BCVA在前6个月显著改善,从54.8个字母增加到59.5个字母。DEX植入后,CST和黄斑体积均显著下降,并保持这些改善至少12个月。与只需要一次植入的受试者相比,需要第二次DEX植入的受受试者之前注射过更多的抗VEGF药物(6.0 vs 3.0)。结论三分之二的难治性DME需要少于两次的DEX植入才能维持干燥黄斑12个月。早期改用玻璃体内DEX可被视为二线治疗选择,尤其是在新冠肺炎大流行期间。
{"title":"The effect of intravitreal dexamethasone implantation on diabetic macular edema refractory to anti-vascular endothelial growth factor treatment","authors":"Kiyoung Kim, E. Kim, Do Gyun Kim, Seung-Young Yu","doi":"10.1080/17469899.2022.2118715","DOIUrl":"https://doi.org/10.1080/17469899.2022.2118715","url":null,"abstract":"ABSTRACT Purpose To evaluate the efficacy and safety of intravitreal dexamethasone (DEX) implantation for diabetic macular edema (DME) that proved unresponsive to previous anti-vascular endothelial growth factor (VEGF) treatment. Methods This prospective interventional study recruited 91 patients with refractory DME after previous anti-VEGF treatments in one or both eyes. All patients were followed up for at least 12 months. Best-corrected visual acuity (BCVA), central subfield thickness (CST) and macular volume were measured. Results Over the 12 months, a mean of 2.1 ± 0.8 DEX implantations were administered per eye; 26 eyes (28.9%) received 1 implantation, 31 (34.4%) received 2, and 34 (36.7%) received 3. BCVA was significantly improved in the first 6 months, from 54.8 to 59.5 letters. Both CST and macular volume decreased significantly after DEX implantation and maintained these improvements for at least 12 months. Subjects who needed the second DEX implantation had a greater number of prior anti-VEGF injections than did those who needed only one implantation (6.0 vs 3.0). Conclusions Two-thirds of refractory DME required less than two DEX implantations to maintain a dry macula for 12 months. Early switching to intravitreal DEX can be considered as the second-line therapeutic option, especially during the COVID-19 pandemic.","PeriodicalId":39989,"journal":{"name":"Expert Review of Ophthalmology","volume":"17 1","pages":"281 - 287"},"PeriodicalIF":0.7,"publicationDate":"2022-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41561313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role trans-sclera MP-CPC as a primary treatment option in congenital glaucoma management 经巩膜MP-CPC作为先天性青光眼治疗的主要选择
IF 0.7 Q4 OPHTHALMOLOGY Pub Date : 2022-07-04 DOI: 10.1080/17469899.2022.2108790
Medhat A Bakr, Ussama A Moustafa, Majed Al-Subaie, Mohammed A Alfayyadh
ABSTRACT Background Childhood glaucoma is considered one of the main causes of irreversible blindness. Primary congenital glaucoma (PCG) is a rare disease; however, in Middle East countries such as Saudi Arabia, the incidence is high. Research design and methods A retrospective study was conducted at Dhahran Eye Specialist Hospital from September 2016 to March 2020 to evaluate the efficacy and safety of transscleral micropulse cyclophotocoagulation (TS-MPCPC) as a primary procedure in congenital glaucoma and as an adjuvant to prepare the patient for ultimate surgical intervention. Emergent ophthalmic examination under sedation or general anesthesia was done to evaluate the presence of PCG features, measure the intraocular pressure (IOP), horizontal corneal diameter (HCD), and to evaluate the optic disc. Results Twenty-one eyes were included in the study. Cup to disc ratio (CDR) was not decreased postoperatively, and it was found statistically non-significant. There was statistically significant decrease in IOP and horizontal corneal diameter (HCD) (p < 0.001, 0.014), respectively. The mean reduction in IOP was 36%. The final IOP was between 5 and 21 mmHg in all cases. Qualified success was achieved in 17 (81%) eyes and 4 (19%) eyes had surgical failure. Conclusion TS-MPCPC might have effective and safe implications for congenital glaucoma patients.
摘要背景儿童期青光眼被认为是导致不可逆性失明的主要原因之一。原发性先天性青光眼是一种罕见的疾病;然而,在沙特阿拉伯等中东国家,发病率很高。研究设计和方法2016年9月至2020年3月,在达兰眼科专科医院进行了一项回顾性研究,以评估经巩膜微脉冲睫状体光凝术(TS-MPCPC)作为先天性青光眼的主要治疗方法和辅助治疗方法的有效性和安全性,为患者进行最终手术干预做好准备。在镇静或全身麻醉下进行紧急眼科检查,以评估PCG特征的存在,测量眼压(IOP)、水平角膜直径(HCD),并评估视盘。结果21只眼睛被纳入研究。术后杯盘比(CDR)没有下降,且无统计学意义。IOP和水平角膜直径(HCD)分别有统计学意义的降低(p<0.001,0.014)。IOP平均降低36%。所有病例的最终眼压均在5至21毫米汞柱之间。17眼(81%)手术成功,4眼(19%)手术失败。结论TS-MPCPC可能对先天性青光眼患者具有安全有效的治疗作用。
{"title":"The role trans-sclera MP-CPC as a primary treatment option in congenital glaucoma management","authors":"Medhat A Bakr, Ussama A Moustafa, Majed Al-Subaie, Mohammed A Alfayyadh","doi":"10.1080/17469899.2022.2108790","DOIUrl":"https://doi.org/10.1080/17469899.2022.2108790","url":null,"abstract":"ABSTRACT Background Childhood glaucoma is considered one of the main causes of irreversible blindness. Primary congenital glaucoma (PCG) is a rare disease; however, in Middle East countries such as Saudi Arabia, the incidence is high. Research design and methods A retrospective study was conducted at Dhahran Eye Specialist Hospital from September 2016 to March 2020 to evaluate the efficacy and safety of transscleral micropulse cyclophotocoagulation (TS-MPCPC) as a primary procedure in congenital glaucoma and as an adjuvant to prepare the patient for ultimate surgical intervention. Emergent ophthalmic examination under sedation or general anesthesia was done to evaluate the presence of PCG features, measure the intraocular pressure (IOP), horizontal corneal diameter (HCD), and to evaluate the optic disc. Results Twenty-one eyes were included in the study. Cup to disc ratio (CDR) was not decreased postoperatively, and it was found statistically non-significant. There was statistically significant decrease in IOP and horizontal corneal diameter (HCD) (p < 0.001, 0.014), respectively. The mean reduction in IOP was 36%. The final IOP was between 5 and 21 mmHg in all cases. Qualified success was achieved in 17 (81%) eyes and 4 (19%) eyes had surgical failure. Conclusion TS-MPCPC might have effective and safe implications for congenital glaucoma patients.","PeriodicalId":39989,"journal":{"name":"Expert Review of Ophthalmology","volume":"17 1","pages":"289 - 294"},"PeriodicalIF":0.7,"publicationDate":"2022-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47720121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Decision-making when your patient has an open globe injury 当你的病人有开放性眼球损伤时的决策
IF 0.7 Q4 OPHTHALMOLOGY Pub Date : 2022-07-04 DOI: 10.1080/17469899.2022.2124969
F. Kuhn
It is not a pretty picture. Today we have the finest tools for diagnostics and a full armamentarium of therapeutics including intraocular drugs, temporary keratoprosetheses (TKP), vitrectomy equipment and instruments; yet more and more patients find out that what determines their fate is indeed fate. Does the facility where s/he is taken keep its operationroom doors open afterhours? Even if yes, is the available staff well trained and all necessary tools accessible? In this publication I summarize my personal opinion regarding the decisions to be made for patients presenting with an open globe injury (OGI) – assuming that the facility is a 24/7 one with all the required logistics/infrastructure being optimal. This also means that the physician to make the decisions and perform the surgery is not an untrained, young resident (as unfortunately so often the case is) but a surgeon experienced in both ‘segments’ of the eye: i.e. a vitreoretinal specialist. If these criteria are not fulfilled, it may be preferable to transport/refer the patient to a different facility where conditions allow optimal treatment. Roughly half of eyes with an OGI require surgery on the posterior segment; if these pathologies cannot be addressed by the surgeon closing the wound, the delay may lead to irreversible damage.
这不是一幅美好的图景。今天,我们拥有最好的诊断工具和全套治疗手段,包括眼内药物、临时角膜假体(TKP)、玻璃体切割设备和仪器;然而,越来越多的病人发现,决定他们命运的确实是命运。他/她所在的工厂是否在下班后保持操作室的门开着?即使是,可用的员工是否受过良好的培训,所有必要的工具是否可用?在这篇文章中,我总结了我个人对开放性球体损伤(OGI)患者的决定的看法——假设该设施是全天候的,所有所需的后勤/基础设施都是最佳的。这也意味着做决定和实施手术的医生不是一个未经训练的年轻住院医生(不幸的是,这种情况经常发生),而是一个在眼睛的两个“部分”都有经验的外科医生:即玻璃体视网膜专家。如果不符合这些标准,最好将患者转移/转诊到条件允许最佳治疗的其他机构。大约一半的OGI眼睛需要在后段进行手术;如果这些病理不能通过外科医生闭合伤口来解决,延误可能导致不可逆转的损伤。
{"title":"Decision-making when your patient has an open globe injury","authors":"F. Kuhn","doi":"10.1080/17469899.2022.2124969","DOIUrl":"https://doi.org/10.1080/17469899.2022.2124969","url":null,"abstract":"It is not a pretty picture. Today we have the finest tools for diagnostics and a full armamentarium of therapeutics including intraocular drugs, temporary keratoprosetheses (TKP), vitrectomy equipment and instruments; yet more and more patients find out that what determines their fate is indeed fate. Does the facility where s/he is taken keep its operationroom doors open afterhours? Even if yes, is the available staff well trained and all necessary tools accessible? In this publication I summarize my personal opinion regarding the decisions to be made for patients presenting with an open globe injury (OGI) – assuming that the facility is a 24/7 one with all the required logistics/infrastructure being optimal. This also means that the physician to make the decisions and perform the surgery is not an untrained, young resident (as unfortunately so often the case is) but a surgeon experienced in both ‘segments’ of the eye: i.e. a vitreoretinal specialist. If these criteria are not fulfilled, it may be preferable to transport/refer the patient to a different facility where conditions allow optimal treatment. Roughly half of eyes with an OGI require surgery on the posterior segment; if these pathologies cannot be addressed by the surgeon closing the wound, the delay may lead to irreversible damage.","PeriodicalId":39989,"journal":{"name":"Expert Review of Ophthalmology","volume":"17 1","pages":"227 - 229"},"PeriodicalIF":0.7,"publicationDate":"2022-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48321212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The application of advanced imaging techniques in glaucoma 先进成像技术在青光眼中的应用
IF 0.7 Q4 OPHTHALMOLOGY Pub Date : 2022-05-04 DOI: 10.1080/17469899.2022.2101449
S. Young, Nikhil Jain, A. Tatham
ABSTRACT Introduction Imaging technologies, especially optical coherence tomography (OCT), have an important role in glaucoma diagnosis and monitoring. This review aims to critically appraise recent developments in imaging of the optic nerve head (ONH), retinal nerve fiber layer (RNFL), and macula in glaucoma. Areas covered The review focuses on imaging of the ONH, retina, and associated structures, identifying five broad themes; 1) imaging of the RNFL, ONH and macula; 2) OCT angiography (OCTA); 3) structure function analysis; 4) novel methods of retinal imaging (beyond OCT and OCTA); and 5) artificial intelligence (AI). The use of imaging for glaucoma diagnosis and progression analysis is discussed. Expert opinion Measurements of RNFL, macular, and ONH have shown similar ability to detect glaucoma, though the majority of OCT diagnostic ability studies are limited by case-control design. Macular and ONH parameters such as Bruch’s membrane opening-minimum rim width (BMO-MRW) may be more useful in eyes with unusual optic disc appearance or high myopia, though the limitations of normative reference databases should be appreciated. Imaging should not replace perimetry, particularly for monitoring progression. Devices are likely to be developed that test structure and function concurrently, with results integrated using Bayesian statistical approaches.
摘要引言成像技术,特别是光学相干断层扫描(OCT),在青光眼的诊断和监测中发挥着重要作用。这篇综述旨在批判性地评价青光眼视神经头(ONH)、视网膜神经纤维层(RNFL)和黄斑成像的最新进展。涵盖的领域该综述侧重于ONH、视网膜和相关结构的成像,确定了五个广泛的主题;1) RNFL、ONH和黄斑的成像;2) OCT血管造影术(OCTA);3) 结构功能分析;4) 视网膜成像的新方法(OCT和OCTA之外);以及5)人工智能(AI)。讨论了影像学在青光眼诊断和进展分析中的应用。专家意见RNFL、黄斑和ONH的测量显示出类似的检测青光眼的能力,尽管大多数OCT诊断能力研究受到病例对照设计的限制。黄斑和ONH参数,如Bruch膜开口最小边缘宽度(BMO-MRW),可能对视盘外观异常或高度近视的眼睛更有用,但应注意规范参考数据库的局限性。影像学不应取代视野检查,尤其是用于监测进展情况。可能会开发同时测试结构和功能的设备,并使用贝叶斯统计方法集成结果。
{"title":"The application of advanced imaging techniques in glaucoma","authors":"S. Young, Nikhil Jain, A. Tatham","doi":"10.1080/17469899.2022.2101449","DOIUrl":"https://doi.org/10.1080/17469899.2022.2101449","url":null,"abstract":"ABSTRACT Introduction Imaging technologies, especially optical coherence tomography (OCT), have an important role in glaucoma diagnosis and monitoring. This review aims to critically appraise recent developments in imaging of the optic nerve head (ONH), retinal nerve fiber layer (RNFL), and macula in glaucoma. Areas covered The review focuses on imaging of the ONH, retina, and associated structures, identifying five broad themes; 1) imaging of the RNFL, ONH and macula; 2) OCT angiography (OCTA); 3) structure function analysis; 4) novel methods of retinal imaging (beyond OCT and OCTA); and 5) artificial intelligence (AI). The use of imaging for glaucoma diagnosis and progression analysis is discussed. Expert opinion Measurements of RNFL, macular, and ONH have shown similar ability to detect glaucoma, though the majority of OCT diagnostic ability studies are limited by case-control design. Macular and ONH parameters such as Bruch’s membrane opening-minimum rim width (BMO-MRW) may be more useful in eyes with unusual optic disc appearance or high myopia, though the limitations of normative reference databases should be appreciated. Imaging should not replace perimetry, particularly for monitoring progression. Devices are likely to be developed that test structure and function concurrently, with results integrated using Bayesian statistical approaches.","PeriodicalId":39989,"journal":{"name":"Expert Review of Ophthalmology","volume":"17 1","pages":"183 - 197"},"PeriodicalIF":0.7,"publicationDate":"2022-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45575561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Straylight in fish-eye disease: visual quality and angular dependence of straylight 鱼眼病的散光:散光的视觉质量和角度依赖性
IF 0.7 Q4 OPHTHALMOLOGY Pub Date : 2022-05-04 DOI: 10.1080/17469899.2022.2098717
Didrika S. van de Wouw, Bram de Jong, I. van der Meulen, T. van den Berg
ABSTRACT Aim To quantify visual complaints by determining straylight values, to investigate the angular dependency of straylight, and to examine the use of straylight for clinical decision making in fish-eye disease (FED) patients. Research design and methods Straylight was measured in 10 patients with FED using the compensation comparison method (Oculus C-Quant). Additionally, the direct comparison method was used for four patients to measure straylight at different visual angles. Results Average straylight in untreated eyes with FED was 1.91 log(s). Penetrating keratoplasty and deep anterior Lamellar keratoplasty treated eyes had average straylight levels of 1.53 log(s) and 1.63 log(s), respectively. Straylight in FED was not strongly angle dependent. Conclusions Straylight was highly elevated (up to 24x age normal value) although visual acuity was relatively well preserved. For several patients, complaints were severe enough to undergo corneal transplantation resulting in reduced straylight and alleviation of complaints. Straylight in FED follows relatively normal angular dependence. We conclude that straylight measurements can support clinical decision-making by quantifying complaints about reduced visual quality, even if visual acuity remains normal.
摘要目的通过测定杂散光值来量化视觉主诉,研究杂散光的角度依赖性,并检验杂散光在鱼眼病(FED)患者临床决策中的应用。研究设计和方法采用补偿比较法(Oculus C-Quant)测量10例FED患者的Straylight。此外,对四名患者采用直接比较法测量不同视角下的杂散光。结果FED未治疗眼的平均散光为1.91 log(s)。穿透性角膜移植术和深前板层角膜移植术治疗的眼睛的平均杂散光水平分别为1.53 log(s)和1.63 log(s.)。FED中的Straylight没有强烈的角度依赖性。结论斜视高度升高(高达24倍年龄正常值),但视力相对较好。对于一些患者来说,主诉严重到可以进行角膜移植,从而减少了散光并减轻了主诉。FED中的Straylight遵循相对正常的角度依赖性。我们得出的结论是,即使视力保持正常,杂散光测量也可以通过量化视觉质量下降的投诉来支持临床决策。
{"title":"Straylight in fish-eye disease: visual quality and angular dependence of straylight","authors":"Didrika S. van de Wouw, Bram de Jong, I. van der Meulen, T. van den Berg","doi":"10.1080/17469899.2022.2098717","DOIUrl":"https://doi.org/10.1080/17469899.2022.2098717","url":null,"abstract":"ABSTRACT Aim To quantify visual complaints by determining straylight values, to investigate the angular dependency of straylight, and to examine the use of straylight for clinical decision making in fish-eye disease (FED) patients. Research design and methods Straylight was measured in 10 patients with FED using the compensation comparison method (Oculus C-Quant). Additionally, the direct comparison method was used for four patients to measure straylight at different visual angles. Results Average straylight in untreated eyes with FED was 1.91 log(s). Penetrating keratoplasty and deep anterior Lamellar keratoplasty treated eyes had average straylight levels of 1.53 log(s) and 1.63 log(s), respectively. Straylight in FED was not strongly angle dependent. Conclusions Straylight was highly elevated (up to 24x age normal value) although visual acuity was relatively well preserved. For several patients, complaints were severe enough to undergo corneal transplantation resulting in reduced straylight and alleviation of complaints. Straylight in FED follows relatively normal angular dependence. We conclude that straylight measurements can support clinical decision-making by quantifying complaints about reduced visual quality, even if visual acuity remains normal.","PeriodicalId":39989,"journal":{"name":"Expert Review of Ophthalmology","volume":"17 1","pages":"221 - 225"},"PeriodicalIF":0.7,"publicationDate":"2022-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44039692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Expert Review of Ophthalmology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1